Repurposing celecoxib analogues as leads for antibiotics.

There is an urgent need for new antibiotics and alternative strategies to combat bacterial pathogens. Molecular docking, antibacterial evaluation and , cytotoxicity assessment and enzyme inhibition analyses were performed. Compound exhibited antimicrobial activity against (MIC: 4 μg/ml), various clinically isolated strains of MRSA (MIC: 4-16 μg/ml) and (MIC: 4 μg/ml) when combined with subinhibitory concentrations of colistin B. Compound (20 mg/kg) yielded mild improvement in survival of methicillin-resistant  (MRSA)-infected mice. Additionally, enzyme inhibition tests showed that compound exhibited inhibitory effects against dihydrofolate reductase (105.1 μg/ml) and DNA gyrase (122.8 μg/ml). Compound is a promising antibacterial candidate for further development.